Takeda continues research accord with Chemizon

Colorado, USA-based Chemizon, a division of Optomagic, says that the US subsidiary of leading Japense drugmaker Takeda Pharmaceutical has agreed to continue and further expand its current research collaboration that utilizes Chemizon's discovery platform. The expansion is effective as of April 1, it noted.

"We are pleased that Takeda has decided to further expand its partnership with Chemizon," said Tony Piscopio, chairman of Optomagic, adding: "with our recently announced strategic partnership in the area of oncology, we anticipate working with our partners and leveraging our integrated discovery platform."

Chemizon says it is a rapidly-growing drug discovery services organization with operations in South Korea, China and the USA. Its goal is to become the partner of choice for pharmaceutical and biotechnology companies seeking to enhance their product pipelines.